“Firstly, phosphate binders calcium carbonate and citrate, lanthanum carbonate, sevelamer and — occasionally — aluminum hydroxide), commonly used in patients on haemodialysis (HD) and very infrequently administered in earlier CKD stages, could substantially affect acetylsalicylic acid (ASA) bioavailability.”